Effects of H1-Antihistamines on hepatocellular carcinoma risk in patients with type 2 diabetes mellitus

Szu-Yuan Wu; Wan-Ming Chen; Yi-Chan Chen; Ming-Feng Chiang; Ming-Che Lee; Ruey-Shyang Soong

doi:10.1016/j.diabet.2022.101393

Effects of H1-Antihistamines on hepatocellular carcinoma risk in patients with type 2 diabetes mellitus

Szu-Yuan Wu, Wan-Ming Chen, Yi-Chan Chen, Ming-Feng Chiang, Ming-Che Lee, Ruey-Shyang Soong

研究成果: 雜誌貢獻 › 文章 › 同行評審

8 引文斯高帕斯（Scopus）

摘要

PURPOSE: H1-antihistamines (AHs) may exert protective effects against cancer. We investigated the association of AH use with hepatocellular carcinoma (HCC) risk in type 2 diabetes mellitus (T2DM) patients without hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.

METHODS: The data of patients with T2DM enrolled from Taiwan's National Health Insurance Research Database were examined for the period of January 1, 2008, to December 31, 2018. We used the Kaplan-Meier method and Cox proportional hazards regression to evaluate the AH use-HCC risk association.

RESULTS: After 1:1 propensity score matching was performed, the two cohorts were each divided into AH users (n = 47,990) and nonusers (n = 47,990). The risk of HCC was significantly lower in AH users than in AH nonusers (adjusted hazard ratio [aHR]: 0.55 95% confidence interval [95% CI], 0.46 to 0.67; IRR: 0.70; 95% CI, 0.60 to 0.84), respectively. The dose-response relationship between AH use and HCC risk was also observed (aHRs: 0.58, 0.56, 0.50, and 0.41 for 28-35, 36-49, 50-77, and >77 cumulative defined daily doses of AH, respectively).

CONCLUSION: AH use can reduce HCC risk in T2DM patients without HBV or HCV infection in a dose-dependent manner.

原文	英語
文章編號	101393
頁（從 - 到）	101393
期刊	Diabetes and Metabolism
卷	49
發行號	1
早期上線日期	9月 2022
DOIs	https://doi.org/10.1016/j.diabet.2022.101393
出版狀態	已發佈 - 1月 2023

ASJC Scopus subject areas

內分泌
內科學
內分泌學、糖尿病和代謝

UN SDG

此研究成果有助於以下永續發展目標

存取文件

10.1016/j.diabet.2022.101393

其它文件與鏈接

Link to publication in Scopus

引用此

@article{a0498479d1e94d49bdbb67dc486d9112,

title = "Effects of H1-Antihistamines on hepatocellular carcinoma risk in patients with type 2 diabetes mellitus",

abstract = "PURPOSE: H1-antihistamines (AHs) may exert protective effects against cancer. We investigated the association of AH use with hepatocellular carcinoma (HCC) risk in type 2 diabetes mellitus (T2DM) patients without hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.METHODS: The data of patients with T2DM enrolled from Taiwan's National Health Insurance Research Database were examined for the period of January 1, 2008, to December 31, 2018. We used the Kaplan-Meier method and Cox proportional hazards regression to evaluate the AH use-HCC risk association.RESULTS: After 1:1 propensity score matching was performed, the two cohorts were each divided into AH users (n = 47,990) and nonusers (n = 47,990). The risk of HCC was significantly lower in AH users than in AH nonusers (adjusted hazard ratio [aHR]: 0.55 95% confidence interval [95% CI], 0.46 to 0.67; IRR: 0.70; 95% CI, 0.60 to 0.84), respectively. The dose-response relationship between AH use and HCC risk was also observed (aHRs: 0.58, 0.56, 0.50, and 0.41 for 28-35, 36-49, 50-77, and >77 cumulative defined daily doses of AH, respectively).CONCLUSION: AH use can reduce HCC risk in T2DM patients without HBV or HCV infection in a dose-dependent manner.",

keywords = "H1-Antihistamines, Hepatocellular Carcinoma, Type 2 Diabetes Mellitus, dose-dependent, incidence rate ratio",

author = "Szu-Yuan Wu and Wan-Ming Chen and Yi-Chan Chen and Ming-Feng Chiang and Ming-Che Lee and Ruey-Shyang Soong",

note = "Funding Information: Chang Gung Memorial Hospital funding number ( CMRPG2L0091 ) supports Ruey-shyang Soong's work & Lo-Hsu Medical Foundation, LotungPoh-Ai Hospital , supports Szu-Yuan Wu's work (Funding Number: 10908 , 10909 , 11001 , 11002 , 11003 , 11006 ) Publisher Copyright: {\textcopyright} 2022 Elsevier Masson SAS",

year = "2023",

month = jan,

doi = "10.1016/j.diabet.2022.101393",

language = "English",

volume = "49",

pages = "101393",

journal = "Diabetes and Metabolism",

issn = "1262-3636",

publisher = "Elsevier Masson s.r.l.",

number = "1",

}

TY - JOUR

T1 - Effects of H1-Antihistamines on hepatocellular carcinoma risk in patients with type 2 diabetes mellitus

AU - Wu, Szu-Yuan

AU - Chen, Wan-Ming

AU - Chen, Yi-Chan

AU - Chiang, Ming-Feng

AU - Lee, Ming-Che

AU - Soong, Ruey-Shyang

N1 - Funding Information: Chang Gung Memorial Hospital funding number ( CMRPG2L0091 ) supports Ruey-shyang Soong's work & Lo-Hsu Medical Foundation, LotungPoh-Ai Hospital , supports Szu-Yuan Wu's work (Funding Number: 10908 , 10909 , 11001 , 11002 , 11003 , 11006 ) Publisher Copyright: © 2022 Elsevier Masson SAS

PY - 2023/1

Y1 - 2023/1

N2 - PURPOSE: H1-antihistamines (AHs) may exert protective effects against cancer. We investigated the association of AH use with hepatocellular carcinoma (HCC) risk in type 2 diabetes mellitus (T2DM) patients without hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.METHODS: The data of patients with T2DM enrolled from Taiwan's National Health Insurance Research Database were examined for the period of January 1, 2008, to December 31, 2018. We used the Kaplan-Meier method and Cox proportional hazards regression to evaluate the AH use-HCC risk association.RESULTS: After 1:1 propensity score matching was performed, the two cohorts were each divided into AH users (n = 47,990) and nonusers (n = 47,990). The risk of HCC was significantly lower in AH users than in AH nonusers (adjusted hazard ratio [aHR]: 0.55 95% confidence interval [95% CI], 0.46 to 0.67; IRR: 0.70; 95% CI, 0.60 to 0.84), respectively. The dose-response relationship between AH use and HCC risk was also observed (aHRs: 0.58, 0.56, 0.50, and 0.41 for 28-35, 36-49, 50-77, and >77 cumulative defined daily doses of AH, respectively).CONCLUSION: AH use can reduce HCC risk in T2DM patients without HBV or HCV infection in a dose-dependent manner.

AB - PURPOSE: H1-antihistamines (AHs) may exert protective effects against cancer. We investigated the association of AH use with hepatocellular carcinoma (HCC) risk in type 2 diabetes mellitus (T2DM) patients without hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.METHODS: The data of patients with T2DM enrolled from Taiwan's National Health Insurance Research Database were examined for the period of January 1, 2008, to December 31, 2018. We used the Kaplan-Meier method and Cox proportional hazards regression to evaluate the AH use-HCC risk association.RESULTS: After 1:1 propensity score matching was performed, the two cohorts were each divided into AH users (n = 47,990) and nonusers (n = 47,990). The risk of HCC was significantly lower in AH users than in AH nonusers (adjusted hazard ratio [aHR]: 0.55 95% confidence interval [95% CI], 0.46 to 0.67; IRR: 0.70; 95% CI, 0.60 to 0.84), respectively. The dose-response relationship between AH use and HCC risk was also observed (aHRs: 0.58, 0.56, 0.50, and 0.41 for 28-35, 36-49, 50-77, and >77 cumulative defined daily doses of AH, respectively).CONCLUSION: AH use can reduce HCC risk in T2DM patients without HBV or HCV infection in a dose-dependent manner.

KW - H1-Antihistamines

KW - Hepatocellular Carcinoma

KW - Type 2 Diabetes Mellitus

KW - dose-dependent

KW - incidence rate ratio

UR - http://www.scopus.com/inward/record.url?scp=85145415444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85145415444&partnerID=8YFLogxK

U2 - 10.1016/j.diabet.2022.101393

DO - 10.1016/j.diabet.2022.101393

M3 - Article

C2 - 36170945

SN - 1262-3636

VL - 49

SP - 101393

JO - Diabetes and Metabolism

JF - Diabetes and Metabolism

IS - 1

M1 - 101393

ER -

Effects of H1-Antihistamines on hepatocellular carcinoma risk in patients with type 2 diabetes mellitus

摘要

ASJC Scopus subject areas

UN SDG

存取文件

其它文件與鏈接

指紋

引用此